Table 2.

Summary of stratified subgroup analysis of VWF-ADAMTS13 axis-related parameters between unfavorable and favorable clinical outcomes.

VWF: Ag
Endpoints	Number of studies included	Favorable clinical outcomes (total patients, n)	Unfavorable clinical outcomes (total patients, n)	Total patients, n	Standard mean difference, 95%CI	P value	I2
Mortality	17	1538	457	1995	−0.79 [−1.05, −0.52]	p < 0.00001	77 %
ICU admission	9	253	202	455	−0.96 [−1.30, −0.62]	p < 0.00001	61 %
Severity	13	518	409	927	−1.18 [−1.59, −0.77]	p < 0.00001	86 %
VWF: Rco
ICU admission	3	92	59	151	−0.85 [−1.20, −0.50]	p < 0.00001	21 %
Severity	3	150	134	284	−1.29 [−2.30, −0.29]	p = 0.001	91 %
ADAMTS13: Ac
Mortality	13	1322	350	1672	0.78 [0.57, 1.00]	p < 0.00001	55 %
ICU admission	5	152	117	269	0.72 [0.31, 1.13]	p = 0.0006	60 %
Severity	7	261	203	464	0.76 [0.34, 1.19]	p = 0.0004	77 %
VWF: Ag/ADAMTS13: Ac Ratio
Mortality	5	664	174	838	−0.85 [−1.36, −0.33]	p = 0.001	82 %
ICU admission	3	110	74	184	−0.96 [−1.27, −0.64]	p < 0.00001	0 %
Severity	4	147	117	264	−1.06 [−1.61, −0.52]	p = 0.0001	74 %
FVIII
Mortality	8	1067	255	1322	−0.62 [−1.27, −0.04]	p = 0.06	93 %
ICU admission	8	373	255	628	−0.81 [−1.15, −0.47]	p < 0.00001	67 %

Abbreviations: ADAMTS13: Ac, a disintegrin and metalloprotease with thrombospondin type I repeats, member 13: Activity; CI, confidence interval; FVIII, factor VIII; ICU, intense care unit; VWF, von Willebrand factor; VWF: Ag, VWF antigen; VWF: Rco, VWF ristocetin cofactor.